Close
Smartlab Europe
Inizio Ignite

International Space Station Provides Pharmaceutical Insight

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Bristol Myers Evinova Partnership Targets AI-Led Trials

Bristol Myers Squibb has entered a global agreement with...

Lilly Buys Orna for $2.4bn to Advance In Vivo Therapies

Eli Lilly has agreed to acquire in vivo CAR-T...

Study Finds Fenebrutinib Cuts Disability Progression In PPMS

Roche announced late-breaking Phase III data showing that fenebrutinib...
- Advertisement -

The International Space Station could be used to develop pharmaceutical products, including treatments for muscular dystrophy. The multilateral coordination board for International Space Station partner agencies has discussed the use of the facility as a potential test bed for future technologies.  Some of the technologies included biotechnological research, such as the analysis of high-quality protein crystals created on the station that could be used to treat muscular dystrophy.

Further research carried about onboard the station concluded that the low-dose isonising radiation encountered in orbit degrades medications, meaning that further development of space-ready medications will be needed for continued human spaceflight beyond Earth’s orbit.

Latest stories

Related stories

Bristol Myers Evinova Partnership Targets AI-Led Trials

Bristol Myers Squibb has entered a global agreement with...

Lilly Buys Orna for $2.4bn to Advance In Vivo Therapies

Eli Lilly has agreed to acquire in vivo CAR-T...

Study Finds Fenebrutinib Cuts Disability Progression In PPMS

Roche announced late-breaking Phase III data showing that fenebrutinib...

Innovent-Lilly Partnership Expands Global Drug Development

Innovent Biologics has announced a strategic Innovent-Lilly partnership with...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »